Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.

Experimental neurology - 1 Mar 1999

Miller G W, Erickson J D, Perez J T, Penland S N, Mash D C, Rye D B, Levey A I

Abstract excerpt

The vesicular monoamine transporter (VMAT2) has been suggested to be an excellent marker of presynaptic dopaminergic nerve terminals in the striatum of Parkinson's disease patients based on its high level of expression and insensitivity to drugs used to treat the disease. Previous in vivo imaging and postmortem binding studies have detected a loss in striatal VMAT2 binding in Parkinson's diseased (PD) brain;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Specificity
Share to Dopamine Agents
Share to Macaca mulatta

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neostriatum

Share to Neuropeptides

Share to Parkinson Disease

Share to Parkinson Disease, Secondary

Share to Vesicular Monoamine Transport Proteins

Source

Identifiers

PMID: 10192785
DOI: 10.1006/exnr.1998.7008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.PMID 10192785Read ↗

Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.Semantic proximity Read ↗

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditionsSemantic proximity Read ↗

Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicitySemantic proximity Read ↗

Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for ParkinsonismSemantic proximity Read ↗

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer DiseaseSemantic proximity Read ↗

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.Semantic proximity Read ↗

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variantsSemantic proximity Read ↗

Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson’s diseaseSemantic proximity Read ↗

Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compactaSemantic proximity Read ↗

Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells.Semantic proximity Read ↗

Imaging Synaptic Vesicle Protein SV2C with <sup>18</sup> F-UCB-F: An In Vitro Autoradiography and In Vivo NHP PET StudySemantic proximity Read ↗

Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.